Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 9/20 | 0.57 |
| ▸ | ITGA2B | P08514 | 9/20 | 0.57 |
| ▸ | PPARG | P37231 | 2/20 | 0.55 |
| ▸ | GPR34 | Q9UPC5 | 3/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.54 |
| ▸ | MME | P08473 | 1/20 | 0.53 |
| ▸ | ACE | P12821 | 1/20 | 0.53 |
| ▸ | CPA1 | P15085 | 1/20 | 0.53 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29908019 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL2305323 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL2305316 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL119886 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL29401723 | 1.00 | ITGB3 (0.57) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| Dl-Phenylalanine SCHEMBL28338672 | 0.94 | ITGB3 (0.54) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL30117564 | 0.92 | PPARG (0.54) | ITGB3ITGA2BPPARGPTPN1 | |
| SCHEMBL1768605 | 0.92 | PTPN1 (0.51) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL1768601 | 0.92 | PTPN1 (0.51) | ITGB3ITGA2BPPARGGPR34PTPN1 | |
| SCHEMBL31688488 | 0.91 | GPR132 (0.63) | ITGB3ITGA2BPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118530720-A | Preparation method of perovskite quantum dot modified by short-chain amino acid ligand | 南通大学 | 2024-08-23 | — | — | CN | claimed |
| CN-117343128-A | Synthesis method of buserelin | 成都君诚康正生物科技有限公司 | 2024-01-05 | — | — | CN | claimed |
| CN-115073555-A | Method for synthesizing pasireotide | 中国医学科学院药物研究所 | 2022-09-20 | — | — | CN | claimed |
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | BRIGHT PEAK THERAPEUTICS AG (CH) | 2026-05-21 | — | — | US | disclosed |
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | DKS CO. LTD. (JP) | 2026-04-02 | — | — | US | disclosed |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | DKS CO. LTD. (JP) | 2026-02-05 | — | — | US | disclosed |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2026-01-22 | — | — | US | disclosed |
| US-12521441-B2 | Modified IL-2 polypeptides and uses thereof | BRIGHT PEAK THERAPEUTICS AG (CH) | 2026-01-13 | — | — | US | disclosed |
| EP-4613282-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING CENTRAL NERVOUS SYSTEM INJURY/DISEASE | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| EP-4613283-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING NEUROPATHIC PAIN AND/OR INFLAMMATORY PAIN | DKS Co. Ltd. (JP) | 2025-09-10 | — | — | EP | disclosed |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2025-08-07 | — | — | US | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| CN-115015545-A | Chitinase 3-like protein 1-based high-sensitivity liver disease detection kit | 亿彤科技发展(福建)有限公司 | 2022-09-06 | — | — | CN | disclosed |
| CN-114957438-A | Human Abeta 1-42 antigenic determinant polypeptide for detecting Alzheimer disease and preparation method thereof | 亿彤科技发展(福建)有限公司 | 2022-08-30 | — | — | CN | disclosed |
| CN-114920851-A | Abeta 1-42 antigen and application thereof in detecting Abeta 1-42 concentration in Alzheimer patient | 亿彤科技发展(福建)有限公司 | 2022-08-19 | — | — | CN | disclosed |
| CN-114836407-A | Chitinase 3-like protein 1 antigen and method for modifying polypeptide by carrier protein | 亿彤科技发展(福建)有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114774395-A | High-purity chitinase 3-like protein 1 epitope peptide for liver disease detection and preparation method thereof | 亿彤科技发展(福建)有限公司 | 2022-07-22 | — | — | CN | disclosed |
| CN-114621326-A | Aspartic acid pasireotide, intermediate and preparation method thereof | 武汉武药科技有限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| WO-2022038417-A2 | MODIFIED IL-18 POLYPEPTIDES AND USES THEREOF | BRIGHT PEAK THERAPEUTICS AG (CH) | 2022-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260091082-A1 | CYCLIC PEPTIDE DERIVATIVE COMPOSITION FOR TREATING OR PREVENTING EYE DISEASE | ADCY3, GLP1R, PDE6C | ITGB3 796/4885ITGA2B 2246/4885PPARG 418/4885 |
| US-20260139053-A1 | TRISPECIFIC COMPOSITIONS COMPRISING IL-2, VEGF BINDING DOMAINS, AND PD-1 BINDING DOMAINS | PDCD1LG2, PDCD1, IL2 | ITGB3 1229/4885ITGA2B 483/4885PPARG 2050/4885 |
| US-20260035407-A1 | CYCLIC PEPTIDE DERIVATIVE, METHOD FOR PRODUCING SAME, AND COMPOSITION | BDNF, VIP, CA3 | ITGB3 3657/4885ITGA2B 4397/4885PPARG 2140/4885 |
| US-20260022142-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 1361/4885ITGA2B 2376/4885PPARG 544/4885 |
| US-20250250299-A1 | MACROCYCLIC IMMUNOMODULATORS | CD274, PDCD1LG2, PDCD1 | ITGB3 3655/4885ITGA2B 3347/4885PPARG 354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.